Literature DB >> 26746859

The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder.

Eduardo Slatopolsky1.   

Abstract

Mechanistic understanding of secondary hyperparathyroidism, vascular calcification, and regulation of phosphate metabolism in chronic kidney disease (CKD) has advanced significantly in the past five decades. In 1960, Bricker developed the 'intact nephron hypothesis', opening the door for hundreds of investigations. He emphasized that 'as the number of functioning nephrons decreases, each remaining nephron must perform a greater fraction of total renal excretion'. Phosphate per se, independent of Ca(2+) and calcitriol, directly affects the development of parathyroid gland hyperplasia and secondary hyperparathyroidism. Vitamin D receptor, Ca(2+) sensing receptor, and Klotho-fibroblast growth factor (FGF) receptor-1 complex are all significantly decreased in the parathyroid glands of patients with CKD. Duodenal instillation of phosphate rapidly decreases parathyroid hormone release without changes in calcium or calcitriol. The same procedure also rapidly increases renal phosphate excretion independently of FGF-23, suggesting the possibility of an 'intestinal phosphatonin'. These observations suggest a possible 'phosphate sensor' in the parathyroid glands and gastrointestinal tract, although as yet there is no proof for the existence of such a sensor. Evidence shows that phosphate has a key role in parathyroid hyperplasia by activating the transforming growth factor-α-epidermal growth factor receptor complex. Thus, control of serum phosphorus early in the course of CKD will significantly ameliorate the pathological manifestations observed during progressive deterioration of renal function. 0085-2538/
© 2011 The Authors. This is an open access article under the CC BY-NC-SA license (https://creativecommons.org/licenses/by-nc-sa/3.0/).

Entities:  

Keywords:  fractional excretion; intact nephron hypothesis; intestinal phosphatonin; phosphate

Year:  2011        PMID: 26746859     DOI: 10.1038/ki.2011.23

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

Review 1.  CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets.

Authors:  Rosilene Motta Elias; Maria Aparecida Dalboni; Ana Carolina E Coelho; Rosa M A Moysés
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

2.  Effect of parathyroidectomy on bone tissue biomarkers and body composition in patients with chronic kidney disease and secondary hyperparathyroidism.

Authors:  Flavia Ramos de Siqueira; Karin Carneiro de Oliveira; Wagner Vasques Dominguez; César Augusto Madid Truyts; Rosa Maria Affonso Moysés; Luciene Machado Dos Reis; Vanda Jorgetti
Journal:  Eur J Clin Nutr       Date:  2021-01-18       Impact factor: 4.016

Review 3.  Fibroblast growth factor 23-Klotho and hypertension: experimental and clinical mechanisms.

Authors:  Michael Freundlich; Gerardo Gamba; Bernardo Rodriguez-Iturbe
Journal:  Pediatr Nephrol       Date:  2020-11-23       Impact factor: 3.714

4.  Interaction between phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care.

Authors:  Luca De Nicola; Giuseppe Conte; Paolo Chiodini; Pierluigi D'Angiò; Gerardo Donnarumma; Roberto Minutolo
Journal:  J Nephrol       Date:  2013-12-06       Impact factor: 3.902

5.  Phosphate Additive Avoidance in Chronic Kidney Disease.

Authors:  David E St-Jules; David S Goldfarb; Mary Lou Pompeii; Mary Ann Sevick
Journal:  Diabetes Spectr       Date:  2017-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.